Chemoimmunotherapy‐associated CD20 ( MS4A1 ) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies
HemaSphere · 2026-10 · 10 (10)
DOI: 10.1002/hem3.70468 ↗Kurz gefasst
Leserbrief in der Zeitschrift HemaSphere, online erschienen am 30.09.2026. Verfasst von Alberto Guijosa und 18 weiteren Autor:innen. Beteiligte Einrichtung: Bing Center for Waldenström's Macroglobulinemia Dana-Farber Cancer Institute Boston MA USA. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Bing Center for Waldenström's Macroglobulinemia Dana-Farber Cancer Institute Boston MA USA.
- Department of Medicine Harvard Medical School Boston MA USA.
- Department of Biological Chemistry & Molecular Pharmacology Harvard Medical School Boston MA USA.
- Department of Pathology Dana-Farber Cancer Institute Boston MA USA.
- Department of Pathology Brigham and Women's Hospital Boston MA USA.
- Department of Medicine Roger Williams Medical Center Providence RI USA.
ORCID-Profile: Alberto Guijosa, Filip Garbicz, John Hatcher, Amanda Kofides, Shirong Liu, Hao Sun, María L Guerrera, Andrew R Branagan, Shayna R Sarosiek, Jorge J Castillo, Zachary R Hunter, Steven P Treon
Förderung
- NIH HHS
Zitieren
APA
Guijosa, A., Tsakmaklis, N., Dhe-Paganon, S., Garbicz, F., Carrasco, R., Hatcher, J., Ramirez-Gamero, A., Pizzarella, D., Kofides, A., Liu, S., Sun, H., Liu, X., Guerrera, M. L., Branagan, A. R., von Keudell, G., Sarosiek, S. R., Castillo, J. J., Hunter, Z. R., & Treon, S. P. (2026). Chemoimmunotherapy‐associated CD20 ( MS4A1 ) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies. HemaSphere, 10(10). https://doi.org/10.1002/hem3.70468
Vancouver
Guijosa A, Tsakmaklis N, Dhe-Paganon S, Garbicz F, Carrasco R, Hatcher J, et al. Chemoimmunotherapy‐associated CD20 ( MS4A1 ) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies. HemaSphere. 2026;10(10). doi:10.1002/hem3.70468
BibTeX
@article{Guijosa2026,
author = {Guijosa, Alberto and Tsakmaklis, Nickolas and Dhe-Paganon, Sirano and Garbicz, Filip and Carrasco, Ruben and Hatcher, John and Ramirez-Gamero, Andres and Pizzarella, Dominic and Kofides, Amanda and Liu, Shirong and Sun, Hao and Liu, Xia and Guerrera, María L and Branagan, Andrew R and von Keudell, Gottfried and Sarosiek, Shayna R and Castillo, Jorge J and Hunter, Zachary R and Treon, Steven P},
title = {Chemoimmunotherapy‐associated CD20 ( MS4A1 ) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies},
journal = {HemaSphere},
year = {2026},
volume = {10},
number = {10},
doi = {10.1002/hem3.70468}
}
EUVIMED